Male pattern baldness in relation to prostate cancer risks: An analysis in the VITamins and lifestyle (VITAL) cohort study

Prostate

Volumn 75, Issue 4, 2015, Pages 415-423

  Zhou, Cindy Ke ^a,b   Littman, Alyson J ^c,d   Levine, Paul H ^b   Hoffman, Heather J ^b   Cleary, Sean D ^b   White, Emily ^c,e   Cook, Michael B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e USA   (United States)

Author keywords

Androgen; Cohort study; Male pattern baldness; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE TYPE ALOPECIA; PRIORITY JOURNAL; PROSTATE CANCER; ALOPECIA; INCIDENCE; LIFESTYLE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; QUESTIONNAIRE; RISK;

ADULT; AGED; ALOPECIA; COHORT STUDIES; HUMANS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; SURVEYS AND QUESTIONNAIRES;

EID: 84920933844     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22927     Document Type: Article

References (50)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; based on November 2011 SEER data submission, posted to the SEER web site, 2012.
2. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006;11:1388-1413.
3. Al Olama, Kote-Jarai AA, Giles Z, Guy GG, Morrison M, Severi J, Leongamornlert G, Tymrakiewicz DA, Jhavar M, Saunders S, Hopper E, Southey JL, Muir MC, English KR, Dearnaley DR, Ardern-Jones DP, Hall AT, O'Brien AL, Wilkinson LT, Sawyer RA, Lophatananon E, Horwich A, Huddart A, Khoo RA, Parker VS, Woodhouse CC, Thompson CJ, Christmas A, Ogden T, Cooper C, Donovan C, Hamdy JL, Neal FC, Eeles DE, Easton RA, On DF, Treatment BAUSS. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009;41:1058-1060.
4. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951;53:708-728.
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
6. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol 2003;121:1561-1564.
7. Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci 2004;34: 11-16.
8. DemarkWahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Lobaugh B, Mathias BJ, Strigo TS, Paulson DF. Serum androgens: Associations with prostate cancer risk and hair patterning. J Androl 1997;18:495-500.
9. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. II. Androstenedione metabolism in isolated hairs. J Clin Endocrinol Metab 1974;39:1012-1019.
10. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006;55:71-74.
11. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair-follicles (Eg Beard) contain more androgen receptors than those from nonbalding areas of scalp. J Endocrinol 1992;133:141-147.
12. Sawaya ME, Honig LS, Hsia SL. Increased androgen binding-capacity in sebaceous glands in scalp of male-pattern baldness. J Invest Dermatol 1989;92:91-95.
13. Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc 2003;8:20-23.
14. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-240.
15. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974;186:1213-1215.
16. Wu CP, Gu FL. The prostate in eunuchs. Progress in clinical and biological research 1991;370:249-255.
17. Li X, Huang Y, Fu X, Chen C, Zhang D, Yan L, Xie Y, Mao Y, Li Y. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. Mutagenesis 2011;26:371-383.
18. Wang F, Zou YF, Feng XL, Su H, Huang F. CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies. Prostate 2011;71:1167-1177.
19. Chang BL, Zheng SQL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu JF. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002;62:1784-1789.
20. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan CL, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. Functional enhancers at the gene-poor 8q24 cancer-linked locus. Plos Genet 2009;5(8):e1000597.
21. Lu YZ, Zhang Z, Yu HJ, Zheng SL, Isaacs WB, Xu JF, Sun JL. Functional annotation of risk loci identified through genome - wide association studies for prostate cancer. Prostate 2011;71: 955-963.
22. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. Endogenous sex hormones and the risk of prostate cancer: A prospective study. Int J Cancer 2008;122:2345-2350.
23. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer I 2008;100:170-183.
24. Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, DuPre N, Giovannucci E, Mucci LA. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol 2014;65:683-689.
25. Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore longitudinal study of aging. BJU Int 2010;105:824-829.
26. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 2012;62:757-764.
27. Sutcliffe S, Colditz GA. Prostate cancer: Is it time to expand the research focus to early-life exposures? Nat Rev Cancer 2013;13:208-518.
28. Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: A systematic review and meta-analysis. J Am Acad Dermatol 2013;68(6):937-943.
29. Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, Kiemeney LA. Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer 2010;46:3294-3299.
30. Demark-Wahnefried W, Schildkraut JM, Thompson D, Lesko SM, McIntyre L, Schwingl P, Paulson DF, Robertson CN, Anderson EE, Walther PJ. Early onset baldness and prostate cancer risk. Cancer Epidem Biomar 2000;9:325-328.
31. Faydaci G, Bilal E, Necmettin P, Fatih T, Asuman O, Ugur K. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels. Aging Male 2008;11:189-192.
32. Giles GG, Severi G, Sinclair R, English DR, McCredie MRE, Johnson W, Boyle P, Hopper JL. Androgenetic alopecia and prostate cancer: Findings from an Australian case-control study. Cancer Epidem Biomar 2002;11:549-553.
33. Greenwald P, Kirmss DA, Polan V. Physical and demographic features of men before developing cancer of the prostate. J Natl Cancer Inst 1974;53:341-346.
34. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidem Biomar 2000;9:523-527.
35. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D. Risk factors for prostate cancer: A case-control study in Greece. Int J Cancer 1999;80:699-703.
36. Muller DC, Sinclair GG, Hopper R, English JL, Severi DR. Age dependent associations between androgenetic alopecia and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2012; 22(2):209-215.
37. Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB, Schroeder FH. Case-control study of prostatic-cancer in Kyoto, Japan - demographic and some lifestyle risk-factors. Prostate 1989;14:117-122.
38. Thomas JA, Antonelli JA, Banez LL, Hoyo C, Grant D, Demark-Wahnefried W, Platz EA, Gerber L, Shuler K, Eyoh E, Calloway E, Freedland SJ. Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic case-control series of veterans. Cancer Cause Control 2013;24:1045-1052.
39. Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol 2010;34:131-135.
40. Wynder ELMK, Whitmore WF Jr. Epidemiology of cancer of the prostate. Cancer 1971;28:344-360.
41. Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, Bachaud JM, Thiounn N, Cosset JM, Giraud P. Male pattern baldness and the risk of prostate cancer. Ann Oncol 2011;22:1824-1827.
42. Zeigler-Johnson C, Morales KH, Spangler E, Chang BL, Rebbeck TR. Relationship of early-onset baldness to prostate cancer in African-American men. Cancer Epidem Biomar 2013;22:589-596.
43. Zhou CK, Pfeiffer RM, Cleary SD, Hoffman HJ, Levine PH, Chu LW, Hsing AW, Cook MB. Relationship Between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol 2014;15(55):4279.
44. White E, Patterson RE, Kristal AR, Thornquist M, King I, Shattuck AL, Evans I, Satia-Abouta J, Littman AJ, Potter JD. VITamins and lifestyle cohort study: Study design and characteristics of supplement users. Am J Epidemiol 2004;159:83-93.
45. Littman AJ, White E. Reliability and validity of self-reported male balding patterns for use in epidemiologic studies. Ann Epidemiol 2005;15:771-772.
46. Raghunathan TE, Lepkowski JM, Hoewyk JV, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodology 2001;27:85-95.
47. Raghunathan TE, Solenberger P, Hoewyk JV. IVEware: Imputation and Variance Estimation Software Volume 2013 Survey Methodology Program, Survey Research Center, Institute for Social Research, University of Michigan performs.
48. DeMuro-Mercon C, Rhodes T, Girman CJ, Vatten L. Male-pattern hair loss in Norwegian men: A community-based study. Dermatology 2000;200:219-222.
49. Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: The physicians' health study. Arch Intern Med 2000;160:165-171.
50. Yamada T, Hara K, Umematsu H, Kadowaki T. Male pattern baldness and its association with coronary heart disease: A meta-analysis. BMJ open 2013;3.